Evidence map›Paper›PMID 28674362›Full record

ArticleInternal medicine (Tokyo, Japan)2017

The Amelioration of Myelofibrosis with Thrombocytopenia by a JAK1/2 Inhibitor, Ruxolitinib, in a Post-polycythemia Vera Myelofibrosis Patient with a JAK2 Exon 12 Mutation.

Kazuhiko Ikeda, Koki Ueda, Takahiro Sano, Kazuei Ogawa, Takayuki Ikezoe, Yuko Hashimoto, Soji Morishita, Norio Komatsu, Hitoshi Ohto, Yasuchika Takeishi

Open access · diamondAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Kazuhiko IkedaDepartment of Hematology, Fukushima Medical University, Japan.
Koki UedaDepartment of Hematology, Fukushima Medical University, Japan.
Takahiro SanoDepartment of Hematology, Fukushima Medical University, Japan.
Kazuei OgawaDepartment of Hematology, Fukushima Medical University, Japan.
Takayuki IkezoeDepartment of Hematology, Fukushima Medical University, Japan.
Yuko HashimotoDepartment of Pathology and Diagnostic Pathology, Fukushima Medical University, Japan.
Soji MorishitaDepartment of Transfusion Medicine and Stem Cell Regulation, Juntendo University Graduate School of Medicine, Japan.
Norio KomatsuDepartment of Hematology, Juntendo University School of Medicine, Japan.
Hitoshi OhtoDepartment of Transfusion and Transplantation Immunology, Fukushima Medical University, Japan.
Yasuchika TakeishiDepartment of Cardiovascular Medicine, Fukushima Medical University, Japan.
Fukushima Medical University · JPJuntendo University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Less than 5% of patients with polycythemia vera (PV) show JAK2 exon 12 mutations. Although PV patients with JAK2 exon 12 mutations are known to develop post-PV myelofibrosis (MF) as well as PV with JAK2V617F, the role of JAK inhibitors in post-PV MF patients with JAK2 exon 12 mutations remains unknown. We describe how treatment with a JAK1/2 inhibitor, ruxolitinib, led to the rapid amelioration of marrow fibrosis, erythrocytosis and thrombocytopenia in a 77-year-old man with post-PV MF who carried a JAK2 exon 12 mutation (JAK2H538QK539L). This case suggests that ruxolitinib is a treatment option for post-PV MF in patients with thrombocytopenia or JAK2 exon 12 mutations.

Indexed as

Aged, 80 and overExonsHumansJanus Kinase 2MaleMutationNitrilesPolycythemiaPolycythemia VeraPrimary MyelofibrosisPyrazolesPyrimidinesThrombocytopeniaJanus Kinase 2NitrilesPyrazolesPyrimidinesruxolitinibJAK2 exon 12 mutationmyelofibrosispolycythemia veraruxolitinibthrombocytopenia

Identifiers

PMID28674362
PMCPMC5519475
OpenAlexW2726232197

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.